**Core tip:** The economic burden of liver cancer worldwide remains great. As a new therapeutic method, pulsed electric field ablation has revolutionized the treatment of liver cancer since this method is different from traditional thermal ablation. We focus on the safety of irreversible electroporation in the clinical treatment of liver cancer and the evaluation of imaging technology. We also review preclinical studies of electrochemotherapy and nanosecond pulsed electric field for liver cancer.

INTRODUCTION
============

Over the last couple of decades, the total number of liver cancer cases has been increasing as the population ages and grows\[[@B1]\]. During the next decade, further increases in the number of new cases of primary liver cancer is predicted each year in most studied countries as a result of changes in risk factors\[[@B2]\]. However, the global hepatocellular carcinoma (HCC) burden can be reduced by administering universal hepatitis B virus vaccinations, avoiding environmental and lifestyle risk factors, and broadly implementing HCC surveillance in high-risk patients\[[@B3]\]. Biannual liver ultrasonography (US) is recommended for patients with cirrhosis because these examinations increase the detection rate of very early HCCs for which effective therapies are feasible\[[@B4]\].

On account of involving a complex decision-making process, HCC management requires a multidisciplinary approach to achieve the best outcome\[[@B5]\]. Patients with early-stage HCC may be treated by surgical resection, liver transplantation, and percutaneous ablation\[[@B6]\]. Surgical resection was previously recommended as the first-line choice for radical treatment, but almost 70% of patients who underwent surgical resection developed recurrent HCC\[[@B7]\]. Although liver transplantation is the best treatment option for HCC, the shortage of available organ donors is the main limiting factor\[[@B8]\]. Percutaneous ablation includes radiofrequency ablation, microwave ablation, cryoablation, and percutaneous ethanol injection, which have evolved considerably over the past 20 years, enabling treatment of an increasing number of patients\[[@B6]\]. Classical monopolar radiofrequency ablation (RFA) possibly has the same therapeutic effect as surgical resection for HCC tumors less than 2--3 cm developing on cirrhotic liver, but the outcomes are still affected by local and distant tumor recurrence\[[@B9]\]. The therapeutic response to RFA is limited for tumors larger than 2 to 3 cm, as well as for tumors located near a major vessel\[[@B10]\]. Since microwave ablation heats up more rapidly and reaches a higher temperature than RFA, this method seems to be an alternative to monopolar RFA for HCC tumors less than 3 cm, especially for multiple HCC tumors\[[@B9]\]. In first-generation cryoablation devices, there is an increased rate of adverse events after ablation compared to that after RFA\[[@B11]\]. Ethanol injection still has a role in high-resource countries for tumor nodules less than 2 cm adjacent to large intrahepatic vessels or bile ducts\[[@B12]\].

Pulsed electric field ablation for liver cancer is a novel ablation modality based on short electric pulses inducing important nonthermal changes in cell physiology. Pulsed electric field ablation for liver cancer mainly encompasses three techniques, including electrochemotherapy (ECT), nanosecond pulsed electric fields (nsPEFs), and irreversible electroporation (IRE). By summarizing the latest advances in different types of pulsed electric field ablation, we hope to promote the study of pulsed electric fields for the treatment of liver cancer.

IRREVERSIBLE ELECTROPORATION
============================

IRE is a nonthermal ablative method that delivers 1-3 kV/cm electric pulses with a pulse width of a millisecond between two electrodes and causes irreversible damage to cells by inducing definitive pores across the cellular membrane\[[@B13]\], while sparing the tissue scaffold, large blood vessels, and other tissue structures (Figure [1A](#F1){ref-type="fig"})\[[@B14]\]. Thus, IRE has been used as an adequate method for the treatment of HCC in cases where traditional methods are unsuitable or deemed to have a high risk for complications\[[@B15]\].

![The basic principle of tumor ablation by pulsed electric fields. A: The pattern of IRE ablation of liver cancer (white cones represent electrodes, and gray sphere represents liver cancer cells); B: The pattern of electrochemotherapy ablation of liver cancer (white cones represent electrodes, gray sphere represents liver cancer cells, and small particles at the top represent chemotherapy drugs); C: The pattern of nanosecond pulsed electric field ablation of liver cancer (white cones represent electrodes, and gray irregular mass represents liver cancer cells).](WJG-26-3421-g001){#F1}

Safety and early efficacy
-------------------------

During the last decade, an increasing number of clinical studies from different countries and regions have evaluated the safety and efficacy of IRE ablation for liver tumors (Table [1](#T1){ref-type="table"}). A recent study from Southeast Asia was conducted by Kalra et al\[[@B16]\] on 21 patients with unresectable HCC. Although the study reported a higher incidence of complications (42.9%), they were mostly mild and did not require additional treatment. Moreover, the investigators found that nodule size (\< 25 mm, *P* = 0.045) was the only factor that significantly affected local tumor progression-free survival\[[@B16]\]. However, Sutter et al\[[@B17]\] found that only the serum α-fetoprotein level (200 ng/mL) (*P* = 0.0004) was correlated with overall tumor progression-free survival. The authors believe that this finding highlights the impact of aggressive growth on cancer treatment\[[@B17]\]. As the largest United Kingdom series on IRE, a bi-institutional review suggests that IRE can be a useful tool for lesions \< 2 cm in size, especially HCC. However, the main limitations of the study include its retrospective design, insufficient sample size, and heterogeneous group of patients with multiple pathologies\[[@B18]\]. Similarly, a study designed in a prospective setting in Japan suggested that after image-guided percutaneous IRE treatment, patients with small HCCs can achieve good local disease control. The reason for the presence of a residual tumor in one (17%) of the six patients with HCCs may be the anatomically unfavorable location of the lesion, inaccurate evaluation performed immediately postoperatively, and strict needle placement requirements\[[@B19]\].

###### 

Summary of major irreversible electroporation trials for liver cancer

  **Ref**.                      **Design**                                    **Number of patients (lesions)**   **Tumor type**                                                 **Tumor size (mm)**                                            **Primary efficacy %**                                                  **Complications**                                                 **Local recurrence**
  ----------------------------- --------------------------------------------- ---------------------------------- -------------------------------------------------------------- -------------------------------------------------------------- ----------------------------------------------------------------------- ----------------------------------------------------------------- ------------------------------
  Kalra et al\[[@B16]\]         Retrospective study                           21 (21)                            21 HCC                                                         26 (14-40)                                                     100%                                                                    42.9% No major complications                                      24%
  Mafeld et al\[[@B18]\]        Bi-institutional retrospective study          52 (59)                            20 HCC; 3 cholangiocellular carcinoma; 33 metastatic disease   24 (7-52)                                                      75%                                                                     17%                                                               Not reported
  Sugimoto et al\[[@B19]\]      Prospective study                             5 (6)                              6 HCC                                                          17.5 (11.2-23.8)                                               83%                                                                     No serious complications                                          Not reported
  Distelmaier et al\[[@B24]\]   Longitudinal observational diagnostic study   29 (43)                            4 HCC; 39 others                                               6.4 (mL)                                                       93%                                                                     Needle tract seeding in 26%, local heating to bile ducts in 24%   5%
  Sutter et al\[[@B17]\]        Retrospective single-center study             58 (75)                            75 HCC                                                         24 (6-90)                                                      77.3% (the first time); 89.35 (the second time); 92% (the third time)   19%                                                               Not reported
  Frühling et al\[[@B20]\]      Single-center nonrandomized clinical study    30 (38)                            23 CRLM; 8 HCC; 7 others                                       24 (0.8--4.0)                                                  78.9% at 3 mo; 65.8% at 6 mo                                            20.0% minor, 3.3% major complications                             21.1% at 3 mo; 34.2% at 6 mo
  Niessen et al\[[@B88]\]       Prospective, single-center study              34 (65)                            33 HCC; 22 CRLM; 10 others                                     24 ± 14 (2-71)                                                 94.5%                                                                   15.71% minor, 11.79% major complication                           13.84%
  Eller et al\[[@B89]\]         Prospective study                             14 (18)                            5 HCC; 11 CRLM; 2 others                                       20 (11-37)                                                     86%                                                                     29%                                                               17%
  Cannon et al\[[@B90]\]        Prospective study                             44 (48)                            14 HCC; 20 CRLM; 10 others                                     HCC 2.1 (1.3--4.5); CRLM 2.7 (1.2--11); other 2.5 (1.1--5.0)   100%                                                                    11.36% (with all complications resolving within 30 d)             Not reported

CRLM: Colorectal liver metastasis; HCC: Hepatocellular carcinoma.

Likewise, in a single-center nonrandomized clinical trial, HCC was most controlled at 3 mo (0% recurrence) compared to colorectal liver metastasis (26.1% recurrence) and other metastases (28.6% recurrence), and smaller tumors can have a lower risk of recurrence\[[@B20]\]. A study by Alnaggar et al\[[@B21]\] pointed out that hepatic injury caused by IRE is transient and self-limiting in patients with HCC and can be monitored by serum transaminases and bilirubin values. Analogously, Froud et al\[[@B22]\] found that although there is a marked increase in liver enzymes after IRE ablation, most of the elevations were safe and self-limiting\[[@B22]\]. In a study evaluating the effect of IRE on vascular patency, only seven (4.4%) of 158 vessels showed abnormal changes. Statistical analysis showed that the presence or absence of vascular abnormalities may not be related to the distance to the ablation site\[[@B23]\]. Unfortunately, in a prospective multi-institution study by Distelmaier et al\[[@B24]\], although local recurrence was found in only two (5%) of the 40 patients with target tumors, needle tract seeding was observed in 27% of patients, and sufficient local heating to the bile ducts was discovered in 22% of patients\[[@B24]\].

A systematic evaluation showed that IRE had a complete response rate of 93% to 100% at 3 mo for HCCs less than 3 cm, with only minor complications during this period\[[@B25]\]. The relevant minor IRE-associated hepatic complications included arrhythmia, portal vein thrombosis, bile duct dilatation, and hepatic abscesses. Fortunately, the majority of these complications did not require further treatment\[[@B26]\]. For instance, vessel narrowing may occur acutely but without long-term sequelae\[[@B27]\]. In general, IRE is a safe and effective method for local ablation. As IRE has become increasingly and widely used in clinical practice, its effect will be further verified.

Examination and evaluation of the ablation area after IRE
---------------------------------------------------------

There have been many studies on the examination and evaluation of ablation effects in animal models. A study of a rodent hepatoma model confirmed that grayscale US, computed tomography (CT), and magnetic resonance imaging (MRI) can be used to distinguish the ablation area from the nonablated area after IRE\[[@B28]\]. All of these modalities, including contrast-enhanced ultrasound (CEUS), CT, and MRI, were able to accurately characterize the ablation effect over a follow-up period of several months\[[@B29]\]. In a study of Yorkshire pigs that compared the results of gross and histopathologic examinations and US, evaluating the hyperechoic rim that appeared 90--120 min after IRE ablation had the best accuracy (± 2 mm)\[[@B30]\]. Another study suggested that 60 to 120 min after IRE ablation would be a suitable time to evaluate the ablation area by US, and this study showed that the appropriate time for CEUS was 10 min after ablation\[[@B31]\]. Nonetheless, in a study on the ablation of normal porcine livers, Schmidt et al\[[@B32]\] found that changes detected by US within minutes of IRE (median, 20 min) were consistent with the area of eventual cellular necrosis\[[@B32]\]. In addition, since the hardness of liver tissue increases after IRE ablation, elastography can be used as an auxiliary means to B-mode US to further detect the ablation effect\[[@B33]\]. CEUS (*r*^2^ = 0.923, *P* \< 0.0001) showed a better correlation with gross pathologic findings than B-mode US (*r*^2^ = 0.905, *P* \< 0.0001)\[[@B34]\].

Although there is a good correlation between contrast-enhanced CT images and histopathology in pig liver models\[[@B35]\], a clinical study found that the normal appearance of enhanced CT images after IRE ablation may be confused with the typical characteristics of potential complications\[[@B36]\]. In a recent porcine liver model study, the three histopathological areas in the ablated area showed different MRI characteristics, and the hepatobiliary phase MRI scans showed the best evaluation ability\[[@B37]\]. Some clinical studies have found that after IRE ablation, MRI scans show large ablation areas that decrease with time\[[@B38]\] and can reflect the morphological and functional changes of the ablation areas\[[@B39]\]. One study suggested that the observation time after ablation should be delayed in the future because the pathological response after ablation in pig liver models lasted for at least 24 h\[[@B40]\]. There are also more novel detection methods that are expected to better reflect the ablation effect of IRE, such as fluorine 18 fluorodeoxyglucose positron emission tomography\[[@B41]\], diffusion-weighted imaging\[[@B42]\], and transcatheter intra-arterial perfusion-MRI\[[@B43]\].

Different tissue types and local environments will affect the ablation effect of IRE\[[@B44]\]. For example, the presence of metal stents in the ablation zone of tumor tissue can affect the temperature around the electrode and residual tissue, but the stents themselves do not significantly increase the temperature\[[@B45]\]. The presence of blood vessels in the ablation area can also lead to inadequate perivascular treatment, which can be prevented by injections of low-conductivity isotonic fluid into hepatic vessels\[[@B46]\].

Optimization of the device
--------------------------

IRE equipment needs to be continuously optimized and improved. For the electrode, the four-electrode array can satisfy the requirements of a larger ablation area within a clinically acceptable time\[[@B47]\]. The use of internally cooled bipolar applicators can reduce tissue temperature (by approximately 10 degrees Celsius) while maintaining good ablation results\[[@B48]\]. It is important to note that the surface temperature of the ordinary electrode will increase significantly, so care should be taken to keep important structures at a distance of 4 mm away from the electrode during ablation\[[@B49]\]. Also, stereotactic navigation and robotic assistance can place electrodes more accurately and quickly than conventional IRE methods while reducing the radiation dose\[[@B50],[@B51]\]. As a novel IRE method, high-frequency irreversible electroporation (H-FIRE) can eliminate muscle contractions that occur during conventional IRE ablation\[[@B52],[@B53]\]. The application of insulated needle electrodes in H-FIRE is expected to further reduce the occurrence of muscle contraction complications\[[@B54]\]. Moreover, the H-FIRE method combined with a single electrode and grounding pad has been demonstrated to be successful for hepatic tissue *in vivo* and can be helpful in situations when placing more than one electrode can be risky\[[@B55]\].

Tumor immunogenicity
--------------------

The effect of IRE ablation on the body\'s immune response has attracted attention. By ablating the livers of miniature pigs and mice, researchers found that two to seven days after IRE ablation, the abnormal Th2 status of animals with HCC was reversed to Th1 status, possibly promoting tumor elimination because the release of pro-inflammatory cytokines in the ablation area stimulated an immune response\[[@B56]\]. Furthermore, the serum output of HCC patients after ablation showed a sharp rise in macrophage migration inhibitory factor followed by a rapid decline, which may contribute to the repair of the ablation area\[[@B57]\]. Additionally, another experiment on IRE ablation in mice showed that the increase in inflammatory cells and cytokines in the IRE ablation area may not only cause tumorigenic effects on the body but also cause the body to generate an immune response\[[@B58]\]. Furthermore, injecting immunogenic adjuvant agents into the tumor before IRE or combining IRE with allogeneic natural killer cell immunotherapy can enhance the body\'s immune response, allowing for better control of the tumor\[[@B59],[@B60]\].

ELECTROCHEMOTHERAPY
===================

ECT is a local treatment for solid tumors that applies short high-intensity pulsed electric fields to improve the transmembrane transfer of cytotoxic drugs (*e.g*., bleomycin and cisplatin) (Figure [1B](#F1){ref-type="fig"})\[[@B61],[@B62]\]. This technique can significantly improve the ability of chemotherapy drugs to kill cancer cells, especially bleomycin\[[@B63],[@B64]\]. ECT has been widely used in the treatment of superficial skin tumors and is expected to play an active role in liver tumors.

Electrochemotherapy in animal trials
------------------------------------

The effects of ECT on HCC in animal models have been studied for more than 20 years. A study of a rat model of HCC found that the ECT group achieved a complete response rate of 69.2%, confirming the effectiveness of ECT in treating HCC\[[@B65]\]. In subsequent studies, good therapeutic effects were also observed in rabbits with transplanted liver tumors and rats with hepatic metastases of colorectal cancer\[[@B66],[@B67]\]. Moreover, studies have shown that ECT does not cause significant damage to normal liver tissue outside the tumor\[[@B68]\] and may stimulate the body\'s immune system\[[@B69]\]. A recent study evaluated whether ECT caused damage to the large blood vessels and bile ducts of the liver through post-ablation liver histology and blood sample tests. Despite the insertion of electrodes into the hepatic vena cava, the researchers found no thrombosis and no significant damage to the blood vessels or bile ducts in the parenchyma. The study further confirmed the safety of ECT for normal liver tissue\[[@B70]\]. Furthermore, the safety of ECT was also verified by radiological findings\[[@B71]\]. Additionally, for tumor blood vessels, ECT can not only cause vasoconstriction in the short term like electroporation but can also further reduce blood flow in the long term. As HCC is a vascular cancer, this characteristic highlights the great potential of ECT as a treatment for HCC\[[@B72]\]. Clearly, the results of the study support the feasibility of using ECT as a modality for treating HCC.

Electrochemotherapy in human clinical trials
--------------------------------------------

The clinical application of ECT in the treatment of HCC has been limited. In the treatment of hepatic metastases of colorectal cancer with ECT, investigators found no serious complications associated with ECT either intraoperatively or postoperatively. In addition, pathological analysis showed that 9.9 ± 12.2% (AM ± SD) of the metastatic foci remained in the treatment group, and radiological results showed that 85% of the 27 metastatic foci had a complete response\[[@B73]\]. Another recent clinical study evaluated the safety and efficacy of ECT in the treatment of six patients with portal vein tumor thrombosis at the hepatic hilum, including three who had sustained thrombus reduction and two who had completely unblocked portal veins; none of these patients developed local recurrence\[[@B74]\]. Based on the previous positive results of ECT, Djokic et al\[[@B75]\] conducted a prospective study on ECT for HCC. The median size of the treated lesions was 24 mm (range 8-41 mm), and the lesions were located near the major hepatic vessels or peripherally. The results showed that at 3 to 6 mo, eight of ten patients achieved complete remission without serious treatment-related complications\[[@B75]\]. These three kinds of liver lesions were treated with ECT and good results were achieved, indicating that ECT could be applied to liver diseases.

NANOSECOND PULSED ELECTRIC FIELDS
=================================

With short pulse durations, nsPEF modulates cell signaling from the plasma membrane to intracellular structures and can affect cell functions\[[@B76]\]. nsPEF-induced apoptosis is independent of plasma membrane electroporation and thermal changes and occurs by recruiting intracellular and plasma membrane apoptosis signaling mechanisms (Figure [1C](#F1){ref-type="fig"})\[[@B77]\].

In vitro studies
----------------

The effects of nsPEFs on cells are multifold. After treating human HCC cells with different pulse parameters, He et al\[[@B78]\] observed changes in cell apoptosis morphology, mitochondrial membrane potential, intracellular calcium ion concentration, and key apoptotic factors and found that the mechanism of cell apoptosis might be a mitochondrial-dependent pathway\[[@B78]\]. In addition, Steuer et al\[[@B79]\] studied changes in cellular elasticity and tumorigenic properties of monolayer rat hepatic epithelial cells treated with nsPEFs. The results showed that the cell elasticity and cytoskeleton changed within 1 h after treatment. Fortunately, the cells did not develop the same malignant features as metastases\[[@B79]\]. Another study found that nsPEFs may temporarily inhibit WB-F344 cell communication by activating mitogen-activated protein kinase\[[@B80]\]. Moreover, by evaluating the electrical parameters, bioimpedance analyses can effectively detect changes in cell-cell contact and paracellular permeability\[[@B81]\]. Using CCK-8, FCM, JC-1, and fluorescent probes to detect the effects after treatment, a recent *in vitro* study examined the different effects of both nsPEFs and baicalin on hepatoma cells and hepatocytes. The results showed that almost all HCC cells in the nsPEFs treatment group died from necrosis, while most hepatocytes died from apoptosis. The combined treatment of nsPEFs and baicalin not only further enhanced the inhibitory effect of nsPEFs on HCC cells but also reduced the damaging effect of nsPEFs on liver cells\[[@B82]\]. The clinical application of this novel treatment may reduce the damage to normal tissues and enhance the ablation effect on tumor tissues.

In vivo studies
---------------

In an animal study, Chen et al\[[@B83]\] induced tumor formation in C57BL/6 mice with hepal-6 HCC cells and then ablated tumor tissue with certain nsPEF parameters. The ultrasound results showed that the cure rate of HCC in mice was 75% and there was no recurrence within 9 mo. In addition, the immunohistochemical results suggest that nsPEF plays a role mainly by inducing apoptosis and inhibiting angiogenesis. The results provide a theoretical basis for nsPEFs in other preclinical and clinical studies. Encouragingly, in a nude mouse xenograft model using a highly metastatic HCC cell line, Yin et al\[[@B84]\] found that nsPEFs can inhibit tumor growth locally in a dose-dependent manner and reduce distant lung metastasis\[[@B84]\]. However, Chen et al\[[@B85]\] found that repeated pulse applications at small doses can increase the infiltration of tumor macrophages\[[@B85]\]. One study suggested that the mechanism of HCC apoptosis included an intrinsic apoptosis mechanism(s) and caspase-independent mechanisms. Notably, rats that had been treated with nsPEF ablation could not regrow tumors when reinjected with N1-S1 HCC cells.

Given the presence of immune cells and granzyme B-expressing cells after ablation, researchers believe that this finding is due to an acquired antitumor response\[[@B86]\]. Nuccitelli et al\[[@B87]\] demonstrated directly for the first time that nsPEF ablation could inhibit the growth of secondary tumors by triggering the production of CD8+ T-cells. The authors found that when CD8+ cytotoxic T-cells were present in the rats, the average size of the secondary tumor was 3% of the size of the primary tumor, and when CD8+ cytotoxic T-cells were absent, the second tumor was 54% of the size of the first tumor. Immunohistochemistry also confirmed the presence of large numbers of CD8+ T-cells in slow-growing secondary tumors. Furthermore, the researchers also found that the mice developed an immune response when injected with tumor cells treated with nsPEFs. The results remained the same even after the anti-CD8 antibodies were injected to deplete CD8+ T-cells\[[@B87]\]. The abovementioned studies undoubtedly confirmed the advantages of nsPEFs in the ablation of HCC.

CONCLUSION
==========

At present, when used as palliative option for patients with HCC who cannot be treated with conventional therapies, IRE has increasingly shown positive clinical effects, especially for small HCC, as the operational and testing equipment has been updated. However, due to the lack of randomized controlled trials on thermal ablation technologies, the indications for IRE need to be explored and verified in more clinical studies\[[@B88]-[@B90]\]. In addition, further studies are needed to evaluate the possible immune effects. For HCC, ECT is a safe and effective approach in preclinical studies, but further validation is needed in clinical studies. As a new treatment method that can induce cell death in many ways and may stimulate the body to produce immune effects, nsPEFs show great potential in the treatment of HCC. However, we have not yet demonstrated the effectiveness of nsPEFs in clinical studies. In the future, to ensure the safety and effectiveness of the application of pulsed electric field ablation in the treatment of HCC, we need to further explore the immune efficacy that pulsed electric field ablation may have in the body.
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